# D3 HERPES SIMPLEX VIRUS IDENTIFICATION KIT

# Applicant

DIAGNOSTIC HYBRIDS, INC. 350 West State Street Athens, OHIO 45701

# Contact Information

Gail R. Goodrum   
Vice President, Regulatory and Quality Affairs   
E-mail: goodrum@dhiusa.com   
Telephone: 740.593.1784   
Desk Extension: 740.593.1787   
FAX: 740.597.1546

# Date of preparation of 510(k) summary:

September 21, 2007 (revised)

# Device Name

Trade name - Diagnostic Hybrids' D3 DFA Chlamydiae Culture Confirmation Kit   
Common name - Fluorescent antibody test for Chlamydiae   
Classification name Antiserum, fluorescent, Chlamydia trachomatis (21 CFR 866.3120,   
product code LJP)

# Legally marketed devices to which equivalence is claimed:

# K864389

American Microscan (distributed by Trinity Biotech) DFA Chlamydia Detection Kit

Kallestad (distributed by BioRad) Pathfinder® Chlamydia Culture Confirmation Kit/System

Diagnostic Products, Corp. (distributed by Remel) PathoDx® Chlamydia Culture Confirmation Kit

# Device Description

The Diagnostic Hybrids' D3 DFA Chlamydiae Culture Confirmation Kit includes a Chlamydiae DFA Reagent that contains a blend of two murine MAbs directed against epitopes on the lipopolysaccharide of Chlamydiae. The kit is used for Chlamydiae detection in cell cultures of patient specimens.

Kit Components: Chlamydiae DFA Reagent - one dropper bottle containing fluorescein labeled murine MAbs directed against Chlamydiae. The buffered, stabilized, aqueous solution contains Evan's Blue as a counter-stain and $0 . 1 \%$ sodium azide as preservative. Chlamydiae Antigen Control Slides - 10 slides. Five individually packaged control slides with wells containing cell culture-derived Chlamydia trachomatis positive cells and five individually packaged control slides with wells containing cell culturederived negative cels. Each slide is intended to be stained only one time. • PBS Concentrate - a 40X concentrate consisting of $4 \%$ sodium azide (after dilution to 1X in water, the concentration of sodium azide in the solution is $0 . 1 \%$ ) in PBS. Mounting Fluid - an aqueous, buffered, stabilized solution of glycerol and $0 . 1 \%$ sodium azide.

The cell cultures to be tested are fixed in acetone. The Chlamydiae DFA Reagent is added to the cells to determine the presence of chlamydial antigens (LPS). After incubating at $3 5 \%$ to $3 7 \%$ , the stained cells are rinsed with the diluted PBS Concentrate, a drop of the supplied Mounting Fluid is added and the monolayer is examined for presence of fluorescent inclusions using a fluorescence microscope equipped with the correct filter combination for FITC at a magnification of 100-400X.

Chlamydiae infected cells will be stained with bright apple-green fluorescence while uninfected cells will contain no apple-green fluorescence but will fluoresce red by the Evan's Blue counter-stain1 which is included in the Chlamydiae DFA Reagent.

If no fluorescent cells are found, report result as, "No Chlamydiae detected". If fluorescent cells are found, indicating a Chlamydiae-positive specimen, report result as, "Chlamydiae isolated by cell culture."

Included in the kit are Chlamydiae Antigen Control Slides. A Control Slide is intended to function as an indicator that the kit reagents are working properly in the test. [The slides are prepared with either Chlamydiae infected cells (Positive Antigen Control Slide) or uninfected cells (Negative Antigen Control Slide).] Positive and negative controls must demonstrate appropriate staining characteristics for specimen results to be valid. Controls may also aid in the interpretation of test results.

It is recommended that cell culture positive (infected with known Chlamydiae isolate) and negative (uninfected cells) controls be run with each assay to provide a means to ensure adequate performance of the cell culture system used. If control cultures fail to perform correctly, results are considered invalid.

Intended Use

The Diagnostic Hybrids' D3 DFA Chlamydiae Culture Confirmation Kit is intended for the qualitative detection of Chlamydiae lipopolysaccharide (LPS) in inoculated cell cultures by immunofluorescence using fluoresceinated monoclonal antibodies (MAbs).

Performance has not been established with direct patient specimens.

Explanation

The test kit uses Chlamydiae antigen-specific murine MAbs that are directly labeled with fluorescein for rapid detection and identification of Chlamydiae.

The cell cultures to be tested are fixed in acetone. The Chlamydiae DFA Reagent is added to the cells to determine the presence of chlamydial antigens. After incubating at $3 5 ^ { \circ } \mathsf { C }$ to $3 7 ^ { \circ } \mathsf { C }$ , the stained cells are rinsed with the diluted PBS Concentrate, a drop of the supplied Mounting Fluid is added and a coverslip is placed on the prepared cells. The cells are examined using a fluorescence microscope.

Technological Characteristics

Fundamental technology and intended use of the device are similar as those of the predicate devices, which are based on a standard immunofluorescence assay technique using cells inoculated with patient specimens. They employ directly labeled fluorescein monoclonal antibodies specific for Chlamydiae antigens enabling visualization of the infected cells. A summary is provided in the table below:

<table><tr><td rowspan=1 colspan=1>ChlamydiaeTest Systems</td><td rowspan=1 colspan=1>DFA</td><td rowspan=1 colspan=1>DirectSpecimens</td><td rowspan=1 colspan=1>CultureConfirmation</td><td rowspan=1 colspan=1>FITCLabel</td><td rowspan=1 colspan=1>MonoclonalAntibody</td><td rowspan=1 colspan=1>Target antigen(epitopes of theChlamydiaelipopolysaccharide)</td></tr><tr><td rowspan=1 colspan=1>Diagnosticybrids</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>AmericanMicroscan</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>Kallestad</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>DiagnosticProducts,Corp.</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td></tr></table>

# Non-clinical Performance

Staining patterns of the conjugated monoclonal antibodies on Chlamydiae infected cells were similar to those of the predicate devices.

The D3 DFA Chlamydiae Culture Confirmation Kit was characterized for its ability to specifically detect Chlamydiae species. The FITC-conjugated MAbs used in the kit exhibited characteristic staining patterns on Chlamydiae infected cells, with fluorescent inclusions in infected cells. The conjugated MAbs reacted with Chlamydophila pneumoniae, Chlamydophila psittaci, as well as 15 serovars of Chlamydia trachomatis.

The ${ \mathsf { D } } ^ { 3 }$ DFA Chlamydiae Culture Confirmation Kit was tested for cross-reactivity against a wide variety of cells and microorganisms. No cross-reactivity was observed for 20 host culture cell types or for 57 virus strains (cultured and processed for staining). Twenty-five (25) bacterial cultures, as well as one protozoan and one yeast specimen, were stained and examined for cross-reactivity. The protein-A produced by Staphylococcus aureus bound the Fc portion of the MAb's and appeared as small points of fluorescence while all other bacterial cultures were negative.

To test this product against Chlamydiae species, cell cultures (McCoy, BGMK, or HEp-2) were inoculated with approximately $1 . 5 \times 1 0 6$ infective units of Chlamydia trachomatis, Chlamydophila psittaci, or Chlamydophila pneumoniae, and incubated for 2 days to yield a $^ { 3 + }$ to $^ { 4 + }$ infection. Cultures were processed and stained with the Chlamydia DFA Reagent or specially prepared DFA reagents containing only one of the Chlamydia MAbs.

Stringent conditions for cross-reactivity testing were achieved by using a high concentration Chlamydiae DFA Reagent and high titers of microorganisms. The DFA was prepared at $1 . 5 \times$ the concentration that is provided in the kit.

Depending on the particular bacteria, the number of CFU tested ranged from $6 . 4 \times 1 0 ^ { 4 }$ to $2 . 9 \times 1 0 ^ { 7 }$ .Depending on the virus, 150 to 2100 $\mathrm { T C i D } _ { 5 0 }$ viruses were inoculated into shell vial culture and incubated for 24 to 48 hours, to yield a $\uparrow +$ to $^ { 3 + }$ infection, processed and stained with the $1 . 5 \times$ DFA according to the procedure detailed in the product insert. Additionally, for some viruses and other microorganisms, commercial slides containing the particular agent were used to test for cross reactivity.

Cell cultures were prepared in shell vial format. Confluent monolayers were stained with the 1.5X DFA Reagent according to the procedure as detailed in this product insert, then examined for cross reactivity.

Organisms and cell lines which were tested against the Chlamydiae DFA Reagent are listed below.

Results of Specificity and Cross Reactivity Testing   

<table><tr><td colspan="5" rowspan="1">MICROORGANISMS (BACTERIA, YEAST, PROTOZOA)</td></tr><tr><td colspan="2" rowspan="2">CHLAMYDIAE</td><td colspan="1" rowspan="2">Serovar</td><td colspan="1" rowspan="2">Inoculum (Infectiveunits per culture)</td><td colspan="1" rowspan="2">Result(Reactive = +)(Negative = -)</td></tr><tr><td colspan="1" rowspan="1"></td></tr><tr><td colspan="2" rowspan="15">Chlamydiatrachomatis</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">A</td><td colspan="1" rowspan="1">1.5x 10^}$</td></tr><tr><td colspan="1" rowspan="1">B</td><td colspan="1" rowspan="1">1.5 x 10}$</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">C</td><td colspan="1" rowspan="1">$1.5x 10}$</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">D</td><td colspan="1" rowspan="1">1.5x10}$</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">E</td><td colspan="1" rowspan="1">1.5x 10^r}$</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">F</td><td colspan="1" rowspan="1">1.5x 10 }$</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">G</td><td colspan="1" rowspan="1">1.5x 10^}$</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">H</td><td colspan="1" rowspan="1">1.5 x 10b}$</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1.5 x 10^}$</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">J</td><td colspan="1" rowspan="1">1.5x 10^}$</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">K</td><td colspan="1" rowspan="1">1.5 x 10 r}$</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">L1</td><td colspan="1" rowspan="1">1.5x 10^}$</td><td colspan="1" rowspan="1">+$</td></tr><tr><td colspan="1" rowspan="1">L2</td><td colspan="1" rowspan="1">1.5x 10}$</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">L3</td><td colspan="1" rowspan="1">1.5x10^}$</td><td colspan="1" rowspan="1">+$</td></tr><tr><td colspan="1" rowspan="1">Ba</td><td colspan="1" rowspan="1">1.5x10^}$</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="3" rowspan="1">Chlamydophila pneumoniae</td><td colspan="1" rowspan="1">1.5x 10^}$</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="3" rowspan="1">Chlamydophila psittaci</td><td colspan="1" rowspan="1">1.5x 10^}$</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="2" rowspan="1">OTHER BACTERIA</td><td colspan="2" rowspan="1">CFU Tested</td><td colspan="1" rowspan="1">Result(Reactive = +)(Negative = -)</td></tr><tr><td colspan="2" rowspan="1">Acholeplasma laidlawi</td><td colspan="2" rowspan="1">~1.0x10</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="2" rowspan="1">Acinetobacter calcoaceticus</td><td colspan="2" rowspan="1">9.7x 10r}$</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="2" rowspan="1">Bordetella bronchiseptica</td><td colspan="2" rowspan="1">1.8x 10^r}$</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="2" rowspan="1">Bordetella pertussis</td><td colspan="2" rowspan="1">4.7× 10^r}$</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="2" rowspan="1">Corynebacterium diphtheriae</td><td colspan="1" rowspan="1">$2.5x 10}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="2" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">$2.6×10^r}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="2" rowspan="1">Gardnerella vaginalis</td><td colspan="1" rowspan="1">5.0 x 10^}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">•</td></tr><tr><td colspan="2" rowspan="1">Haemophilis influenzae type A</td><td colspan="1" rowspan="1">$9.3x 10^}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="2" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">6.4x 10^}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="2" rowspan="1">Legionella pneumophila</td><td colspan="1" rowspan="1">6.5x 10^$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="2" rowspan="1">Moraxella cartarrhalis</td><td colspan="1" rowspan="1">6.4× 10^{}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="2" rowspan="1">Mycoplasma hominis</td><td colspan="1" rowspan="1">~1.0x10^4</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="2" rowspan="1">Mycoplasma orale</td><td colspan="1" rowspan="1">~1.0x10^$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="2" rowspan="1">Mycoplasma pneumoniae</td><td colspan="1" rowspan="1">~1.0x10^4</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="2" rowspan="1">Mycoplasma salivarium</td><td colspan="1" rowspan="1">~1.0x10</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="2" rowspan="1">Neisseria gonorrhoeae</td><td colspan="1" rowspan="1">1.3x 10^}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="2" rowspan="1">Proteus mirabilis</td><td colspan="1" rowspan="1">$2.1x 10^}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="2" rowspan="1">Pseudomonas aeruginosa</td><td colspan="1" rowspan="1">1.0x 10^}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="2" rowspan="1">Salmonella enteriditis</td><td colspan="1" rowspan="1">2.5x10}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="2" rowspan="1">Salmonella typhimurium</td><td colspan="1" rowspan="1">1.8 x 10^r}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="2" rowspan="1">Staphylococcus aureus</td><td colspan="1" rowspan="1">1.0x10</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="2" rowspan="1">Streptococcus agalactiae</td><td colspan="2" rowspan="1">$9.6 x 10fr}$</td><td colspan="1" rowspan="1">*</td></tr><tr><td colspan="2" rowspan="1">Streptococcus pneumoniae</td><td colspan="2" rowspan="1">$8.0x 10^}$</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="2" rowspan="1">Streptococcus pyogenes</td><td colspan="1" rowspan="1">2.9 x 10</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="2" rowspan="1">Ureaplasma urealyticum</td><td colspan="1" rowspan="1">~1.0x10^4</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="2" rowspan="1">YEAST</td><td colspan="2" rowspan="1">CFU Tested</td><td colspan="1" rowspan="1">Result(Reactive = +)(Negative = -)</td></tr><tr><td colspan="2" rowspan="1">Candida glabrata</td><td colspan="2" rowspan="1">8.7x 10r}$</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="2" rowspan="1">PROTOZOAN</td><td colspan="2" rowspan="1">CFU Tested</td><td colspan="1" rowspan="1">Result(Reactive = +)(Negative = -)</td></tr><tr><td colspan="2" rowspan="1">Trichomonas vaginalis</td><td colspan="2" rowspan="1">Commercially availablecontrol slide^</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="2" rowspan="1">VIRUS STRAINS</td><td colspan="2" rowspan="1">Inoculum (TCID5o)</td><td colspan="1" rowspan="1">Result(Reactive = +)(Negative = -)</td></tr><tr><td colspan="1" rowspan="12">Adenovirus</td><td colspan="1" rowspan="1">Type 1</td><td colspan="2" rowspan="1">725</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Type 3</td><td colspan="2" rowspan="1">725</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Type 6</td><td colspan="2" rowspan="1">725</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Type 7</td><td colspan="2" rowspan="1">725</td><td colspan="1" rowspan="1">*</td></tr><tr><td colspan="1" rowspan="1">Type 8</td><td colspan="2" rowspan="1">725</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Type 10</td><td colspan="2" rowspan="1">725</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Type 13</td><td colspan="2" rowspan="1">725</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Type 14</td><td colspan="2" rowspan="1">725</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Type 18</td><td colspan="2" rowspan="1">725</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Type 31</td><td colspan="2" rowspan="1">725</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Type 40</td><td colspan="2" rowspan="1">725</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Type 41</td><td colspan="2" rowspan="1">725</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="2">Influenza A</td><td colspan="1" rowspan="1">Aichi</td><td colspan="2" rowspan="1">$2.1x 10^r}$</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Malaya</td><td colspan="2" rowspan="1">$2.1x10^}$</td><td colspan="1" rowspan="1">*</td></tr><tr><td colspan="1" rowspan="5"></td><td colspan="1" rowspan="1">Hong Kong</td><td colspan="1" rowspan="1">$2.1x 10^r}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Denver</td><td colspan="1" rowspan="1">$2.1x 10^}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Port Chalmers</td><td colspan="1" rowspan="1">2.1 x 10^3</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">PR</td><td colspan="1" rowspan="1">$2.1x 10^r}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Victoria</td><td colspan="1" rowspan="1">$2.1x 10^}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="6">Influenza 8</td><td colspan="1" rowspan="1">Hong Kong</td><td colspan="1" rowspan="1">$2.1x 10^r}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Maryland</td><td colspan="1" rowspan="1">$2.1x 10^{r3}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Mass</td><td colspan="1" rowspan="1">2.1x 10^</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Taiwan</td><td colspan="1" rowspan="1">2.1x 10^{}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">GL</td><td colspan="1" rowspan="1">$2.1x10^}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Russia</td><td colspan="1" rowspan="1">$2.1x 10^r}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">*</td></tr><tr><td colspan="1" rowspan="3">RSV</td><td colspan="1" rowspan="1">Long</td><td colspan="1" rowspan="1">$2.1 x 10^}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Wash</td><td colspan="1" rowspan="1">$2.1x 10^}$</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">9320</td><td colspan="2" rowspan="1">$2.1x10^{}$</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Parainfluenza 1</td><td colspan="1" rowspan="1">C-35</td><td colspan="2" rowspan="1">Commercially availablecontrol slidea</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Parainfluenza 2</td><td colspan="1" rowspan="1">Greer</td><td colspan="2" rowspan="1">Commercially availablecontrol slide</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Parainfluenza 3</td><td colspan="1" rowspan="1">C 243</td><td colspan="2" rowspan="1">Commercially availablecontrol slide</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="2">HSV-1</td><td colspan="1" rowspan="1">1F</td><td colspan="2" rowspan="1">150</td><td colspan="1" rowspan="1">•</td></tr><tr><td colspan="1" rowspan="1">Macintyre</td><td colspan="2" rowspan="1">150</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="2">HSV-2</td><td colspan="1" rowspan="1">MS</td><td colspan="2" rowspan="1">150</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Strain G</td><td colspan="2" rowspan="1">150</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="3">CMV</td><td colspan="1" rowspan="1">Towne</td><td colspan="2" rowspan="1">700</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">AD169</td><td colspan="2" rowspan="1">700</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Davis</td><td colspan="2" rowspan="1">700</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">VZV</td><td colspan="1" rowspan="1">Ellen</td><td colspan="2" rowspan="1">500</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Echovirus</td><td colspan="1" rowspan="1">4, 6, 9, 11, 30, 34</td><td colspan="2" rowspan="1">Commercially availablecontrol slidea</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Coxsackievirus</td><td colspan="1" rowspan="1">B1, B2, B3, B4, B5,B6</td><td colspan="2" rowspan="1">Commercially availablecontrol slidea</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Mumps</td><td colspan="1" rowspan="1"></td><td colspan="2" rowspan="1">Commercially availablecontrol slide$</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Measles (Rubeola)</td><td colspan="1" rowspan="1"></td><td colspan="2" rowspan="1">Commercially availablecontrol slidea</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Poliovirus</td><td colspan="1" rowspan="1">Types 1, 2, 3</td><td colspan="2" rowspan="1">Commercially availablecontrol slidea</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Epstein-Barr</td><td colspan="1" rowspan="1"></td><td colspan="2" rowspan="1">Commercially avaiiablecontrol slide$</td><td colspan="1" rowspan="1"></td></tr></table>

Clinical studies included nine hundred and ninety four (994) original specimens evaluated for the presence of Chlamydiae by this product ("Subject" test) and three currently marketed Culture Confirmation Kits ("Comparison" tests). These evaluations were conducted at three external laboratory sites using one Comparison Device (American Microscan DFA Chlamydia Detection Kit) and one in-house laboratory where the two other Comparison Devices were used: (1) A reference laboratory in the uheastern Unite States; Ahospital aboratory i he mid-west UnitedState ) Ahospital aboratory inthe southwestern United States; and (4) Diagnostic Hybrids' inhouse virology laboratory.

A summary of the specimens by Site is presented in the table below.

Number of Specimens in Each Study Site   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Freshprospective</td><td rowspan=1 colspan=1>Frozenprospective</td><td rowspan=1 colspan=1>Archived(frozen)</td><td rowspan=1 colspan=1>Site Total</td></tr><tr><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>156</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>396</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>187</td><td rowspan=1 colspan=1>278</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>120</td></tr></table>

350 West State Street  Athens. Ohio 45701 1-800-344-5847 •Fax 740-593-0980 •www.ohiusa.com

Percent Agreement and $9 5 \%$ Confidence Interval between the Subject Device and Comparison test for the three external laboratory sites was calculated and is presented in the table below (results from both fresh and frozen specimens are included).

# Percent Agreement of All Tests

<table><tr><td colspan="3">Comparison Device</td></tr><tr><td></td><td>+</td><td></td></tr><tr><td>Subject Device Diagnostic</td><td>+ 42</td><td>4</td></tr><tr><td>Hybrids</td><td>2</td><td>613</td></tr><tr><td>Positive Percent Agreementb (PPA)</td><td>95.5%</td><td></td></tr><tr><td>95% CI- PPA</td><td>84.5%-99.4%</td><td></td></tr><tr><td>Negative Percent Agreement (NPA)</td><td>99.4%</td><td></td></tr><tr><td>95% CI - NPA</td><td>98.3%-99.8%</td><td></td></tr></table>

Ms. Gail R. Goodrum   
Vice President, Regulatory and Quality Affairs Diagnostic Hybrids, Inc.   
350 West State Street   
Athens, OH 45701

Re: k063675 Trade/Device Name: Diagnostic Hybrids' $\mathrm { D } ^ { 3 }$ Chlamydiae Culture Confirmation Kit Regulation Number: 21 CFR $\ S 8 6 6 . 3 1 2 0$ EPY Regulation Name: Chlamydia serological reagents Regulatory Class: I Product Code: LJP Dated: August 10, 2007 Received: August 13, 2007

Dear Ms. Goodrum:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or classIII (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification.The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at 240-276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/650ea7591c057e2f771149979a96ec9b3157c6a4c053198bf785484a4a1aef0d.jpg)

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and   
Radiological Health

# Indications for Use

510(k) Number (if known): _K063675

Device Name: Diagnostic Hybrids' D³ DFA Chlamydiae Culture Confirmation Kit

Indications for Use: The Diagnostic Hybrids' $\mathrm { D } ^ { 3 }$ DFA Chlamydiae Culture Confirmation Kit is intended for the qualitative detection of Chlamydiae lipopolysaccharide (LPS) in inoculated cell cultures by immunofluorescence using fluoresceinated monoclonal antibodies (MAbs).

Performance has not been established with direct patient specimens.

Concurrence of CDRH, Office ofDevice Evaluation (ODE) Une Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510(k) k063675